文献速递泌尿男性生殖肿瘤

膀胱内重组BCG联合围手术期化学免疫治疗肌层浸润性膀胱癌:SAKK 06/19单臂II期试验主要分析

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.
PubMed 文献 · J Clin Oncol · 2026-05-29

主要终点中心审查病理完全缓解(pCR)率为68%(27/40;单侧95%CI下限53%),病理总体缓解(PaR)率为83%(33/40;95%CI 67-93)。结论认为该方案显示较高pCR和PaR率,值得在前瞻性随机试验中进一步研究。

要点

  • 新辅助膀胱内rBCG联合阿替利珠单抗和顺铂/吉西他滨后RC-LND,中心审查pCR达68%。
  • PaR率为83%,rBCG给药完成率95%,78%完成全部三剂。
  • rBCG、阿替利珠单抗和化疗的3级不良事件率分别为9%、15%和38%。

核心结论

  • 在MIBC中,膀胱内rBCG联合化学免疫治疗显示高pCR和PaR率,值得在前瞻性随机试验中进一步研究。

研究设计与样本

  • 设计基于Simon minimax两阶段法,H0 pCR≤35%、H1 pCR≥55%,单侧α5%、把握度80%,需46例。

主要发现

  • 中心审查pCR为68%(27/40;单侧95%CI下限53%),PaR为83%(33/40;95%CI 67-93)。
  • rBCG给药率95%,78%完成全部三剂。

关键数值与推荐

  • 治疗相关不良事件(任何级别/3级/4级):rBCG为42%/9%/0%,阿替利珠单抗为55%/15%/2%,化疗为96%/38%/17%。

临床怎么用

  • 该方案为MIBC新辅助治疗提供含膀胱内rBCG的化学免疫治疗选项,但需随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravesical Bacillus Calmette-Guérin (BCG) is highly effective in non-muscle-invasive bladder cancer (MIBC) but has not been evaluated in MIBC. The recombinant BCG vaccine VPM1002BC (rBCG) has potentially enhanced immunogenicity and an improved safety profile. We investigated neoadjuvant intravesical rBCG combined with chemoimmunotherapy in MIBC. PATIENTS AND METHODS: SAKK 06/19 was an open-label single-arm phase II trial for cT2-T4a N0-1 MIBC eligible for cisplatin and radical cystectomy with lymph node dissection (RC-LND). rBCG was instilled once per week three times starting on day 1. Atezolizumab was administered on day 1 for a total of four doses, and cisplatin/gemcitabine was started on day 22 for four cycles followed by RC-LND. Adjuvant atezolizumab was only administered in the case of >yT1 ypN0. The primary end point was centrally reviewed pathologic complete response (pCR, ypT0 ypN0). Based on Simon's minimax two-stage design with H0 pCR ≤35%, H1 pCR ≥55%, one-sided alpha 5%, and power 80%, 46 patients were needed. Secondary end points included pathologic overall response (PaR, ≤ypT1 ypN0), event-free survival (EFS), overall survival (OS), and safety. RESULTS: Forty-seven patients were included between April 2022 and April 2025. Seven patients did not undergo RC-LND (six declined, one unfit for surgery). rBCG was instilled in 95%, and 78% had all three doses. Centrally reviewed pCR was 68% (27 of 40; one-sided 95% CI lower boundary 53%), and PaR was 83% (33 of 40; 95% CI, 67 to 93). Treatment-related adverse events (any grade, grade 3, grade 4) were 42%, 9%, and 0% for rBCG; 55%, 15%, and 2% for atezolizumab; and 96%, 38%, and 17% for chemotherapy. CONCLUSION: To our knowledge, this is the first trial combining intravesical rBCG with chemoimmunotherapy in MIBC, demonstrating high pCR and PaR rates that warrant further investigation in prospective randomized trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cathomas R, Petrausch U, Hayoz S, et al. Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19. J Clin Oncol. 2026. PMID: 42212670. doi:10.1200/JCO-26-00845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。